Quantitative proteomic approaches in biomarker discovery of inflammatory bowel disease

Abstract

Proteomics offers considerable opportunities for either enhancing our biological understanding or discovering biomarkers, blood and biopsied specimen‐based proteomic approaches, provide reproducible and quantitative tools that can complement clinical assessments and aid clinicians in the diagnosis and treatment of inflammatory bowel disease ( IBD ). Sometimes a differential diagnosis of C rohn's disease ( CD ) and ulcerative colitis ( UC ) and the prediction of treatment response can be deduced by finding meaningful biomarkers, for which the central platform for proteomics is tandem mass spectrometry ( MS / MS ). A range of workflows are available for protein (or peptide) separation prior to MS / MS as well as bioinformatics analysis to achieve protein identification, for which two‐dimensional electrophoresis (2‐ DE ) and subsequent mass spectrometry (MS), liquid chromatography‐ MS , difference gel electrophoresis following 2‐ DE , isobaric tags for relative and absolute quantification (iTRAQ), stable isotope labeling by amino acids and label‐free quantification are under development. In this article, the current status and perspective of these advanced proteomic technologies are introduced, with examples of recent biomarkers focused on the diagnosis, treatment response, prognosis of IBD , and even colitis‐associated carcinogenesis in both animal models and human patients.